Dan Brennan
Stock Analyst at TD Cowen
(3.97)
# 536
Out of 4,412 analysts
48
Total ratings
54.84%
Success rate
9.12%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Buy | $280 → $290 | $246.62 | +17.59% | 3 | Apr 24, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $240 → $300 | $231.77 | +29.44% | 2 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Maintains: Buy | $270 → $290 | $229.00 | +26.64% | 3 | Feb 15, 2024 | |
| ILMN Illumina | Downgrades: Market Perform | n/a | $123.05 | - | 3 | Jan 4, 2024 | |
| NEO NeoGenomics | Maintains: Outperform | $22 → $19 | $13.92 | +36.49% | 5 | Dec 29, 2023 | |
| NTRA Natera | Maintains: Outperform | $82 → $87 | $92.88 | -6.33% | 1 | Dec 12, 2023 | |
| AVTR Avantor | Upgrades: Outperform | $28 | $24.23 | +15.56% | 2 | Dec 11, 2023 | |
| LULU Lululemon Athletica | Maintains: Outperform | $545 → $546 | $360.60 | +51.41% | 4 | Dec 8, 2023 | |
| A Agilent Technologies | Maintains: Outperform | $145 → $147 | $137.04 | +7.27% | 8 | Aug 16, 2023 | |
| MDXH MDxHealth | Initiates: Outperform | $7 | $2.50 | +180.00% | 1 | May 31, 2023 | |
| TXG 10x Genomics | Maintains: Outperform | $62 → $66 | $29.28 | +125.41% | 3 | May 4, 2023 | |
| TMO Thermo Fisher | Maintains: Outperform | $711 → $693 | $568.72 | +21.85% | 4 | Apr 27, 2023 | |
| VZ Verizon | Maintains: Outperform | $49 → $45 | $39.49 | +13.95% | 1 | Apr 26, 2023 | |
| PACB Pacific Biosciences of California | Upgrades: Outperform | $13 → $15 | $1.65 | +809.09% | 1 | Mar 31, 2023 | |
| EXAS Exact Sciences | Maintains: Outperform | $56 → $76 | $59.35 | +28.05% | 3 | Feb 22, 2023 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Neutral | $20 → $16 | $8.20 | +95.12% | 2 | Jan 5, 2023 | |
| ICLR ICON PLC | Upgrades: Buy | n/a | $297.88 | - | 1 | Mar 1, 2021 | |
| MTD Mettler-Toledo International | Downgrades: Sell | n/a | $1,229.70 | - | 1 | Oct 7, 2020 |
Danaher
Apr 24, 2024
Maintains: Buy
Price Target: $280 → $290
Current: $246.62
Upside: +17.59%
IQVIA Holdings
Feb 15, 2024
Maintains: Buy
Price Target: $240 → $300
Current: $231.77
Upside: +29.44%
Charles River Laboratories International
Feb 15, 2024
Maintains: Buy
Price Target: $270 → $290
Current: $229.00
Upside: +26.64%
Illumina
Jan 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $123.05
Upside: -
NeoGenomics
Dec 29, 2023
Maintains: Outperform
Price Target: $22 → $19
Current: $13.92
Upside: +36.49%
Natera
Dec 12, 2023
Maintains: Outperform
Price Target: $82 → $87
Current: $92.88
Upside: -6.33%
Avantor
Dec 11, 2023
Upgrades: Outperform
Price Target: $28
Current: $24.23
Upside: +15.56%
Lululemon Athletica
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $360.60
Upside: +51.41%
Agilent Technologies
Aug 16, 2023
Maintains: Outperform
Price Target: $145 → $147
Current: $137.04
Upside: +7.27%
MDxHealth
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $2.50
Upside: +180.00%
10x Genomics
May 4, 2023
Maintains: Outperform
Price Target: $62 → $66
Current: $29.28
Upside: +125.41%
Thermo Fisher
Apr 27, 2023
Maintains: Outperform
Price Target: $711 → $693
Current: $568.72
Upside: +21.85%
Verizon
Apr 26, 2023
Maintains: Outperform
Price Target: $49 → $45
Current: $39.49
Upside: +13.95%
Pacific Biosciences of California
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.65
Upside: +809.09%
Exact Sciences
Feb 22, 2023
Maintains: Outperform
Price Target: $56 → $76
Current: $59.35
Upside: +28.05%
Maravai LifeSciences Holdings
Jan 5, 2023
Downgrades: Neutral
Price Target: $20 → $16
Current: $8.20
Upside: +95.12%
ICON PLC
Mar 1, 2021
Upgrades: Buy
Price Target: n/a
Current: $297.88
Upside: -
Mettler-Toledo International
Oct 7, 2020
Downgrades: Sell
Price Target: n/a
Current: $1,229.70
Upside: -